» Articles » PMID: 28395545

Lymphoma Classification Update: B-cell Non-Hodgkin Lymphomas

Overview
Specialty Hematology
Date 2017 Apr 12
PMID 28395545
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Lymphomas are classified based on the normal counterpart, or cell of origin, from which they arise. Because lymphocytes have physiologic immune functions that vary both by lineage and by stage of differentiation, the classification of lymphomas arising from these normal lymphoid populations is complex. Recent genomic data have contributed additional complexity. Areas covered: Lymphoma classification follows the World Health Organization (WHO) system, which reflects international consensus and is based on pathological, genetic, and clinical factors. A 2016 revision to the WHO classification of lymphoid neoplasms recently was reported. The present review focuses on B-cell non-Hodgkin lymphomas, the most common group of lymphomas, and summarizes recent changes most relevant to hematologists and other clinicians who care for lymphoma patients. Expert commentary: Lymphoma classification is a continually evolving field that needs to be responsive to new clinical, pathological, and molecular understanding of lymphoid neoplasia. Among the entities covered in this review, the 2016 revision of the WHO classification particularly impact the subclassification and genetic stratification of diffuse large B-cell lymphoma and high-grade B-cell lymphomas, and reflect evolving criteria and nomenclature for indolent B-cell lymphomas and lymphoproliferative disorders.

Citing Articles

Peripheral T-Cell Lymphoma Coexisting with Autoimmune Hemolytic Anemia: Analysis of Clinical Features.

Candan O, Naghizada N, Demirtas D, Yanik A, Salim S, Menguc M Indian J Hematol Blood Transfus. 2025; 41(1):181-185.

PMID: 39917494 PMC: 11794746. DOI: 10.1007/s12288-024-01822-x.


The other side of the coin: protein deubiquitination by Ubiquitin-Specific Protease 1 in cancer progression and therapy.

Hu X, Wu Y, Yao M, Chen Z, Li Q Future Med Chem. 2025; 17(3):329-345.

PMID: 39819213 PMC: 11792837. DOI: 10.1080/17568919.2025.2453414.


Advances in epigenetic therapies for B-cell non-hodgkin lymphoma.

Hu W, Zang L, Feng X, Zhuang S, Chang L, Liu Y Ann Hematol. 2024; 103(12):5085-5101.

PMID: 39652169 DOI: 10.1007/s00277-024-06131-x.


Chidamide represses MYC expression and might improve survival for patients with double expressor lymphoma.

Liu P, Hang X, Li J, Zhao L, Liu W, Ji J Am J Cancer Res. 2024; 14(6):2921-2933.

PMID: 39005667 PMC: 11236771. DOI: 10.62347/GIIR3351.


Burkitt's lymphoma in a young boy progressing to systemic lupus erythematosus during follow-up: a case report and literature review.

Liu C, Pan C, Jin Y, Huang H, Ding F, Xu X Front Pediatr. 2024; 12:1348342.

PMID: 38496369 PMC: 10940322. DOI: 10.3389/fped.2024.1348342.